AbbVie-aktie (ABBV): FDA godkender ny Venclexta-Calquence-kombination til CLL — det skal du holde øje med mandag
The FDA approved a new first-line combination therapy for chronic lymphocytic leukemia using AbbVie’s Venclexta and AstraZeneca’s Calquence, showing improved progression-free survival over standard chemoimmunotherapy. AbbVie shares closed up 0.21% at $224.81 on Friday. Barclays initiated coverage with an overweight rating and $275 price target. Investors await market reaction when trading resumes Monday.